FDA Approves New Drug to Reduce Delusions Associated with Parkinson’s Disease
Parkinson’s disease is well-known for causing tremors and cognitive difficulties. Two of the lesser-known symptoms are delusions and hallucinations, which according to studies occur in as many as 50 percent of Parkinson’s patients. Until recently, there was no approved treatment for these symptoms.
Nuplazid, generic name pimavanserin, is the first drug the U.S. Food and Drug Administration (FDA) has ever approved for the treatment of Parkinson’s-related delusions and hallucinations. Before the approval, Nuplazid passed a six-week clinical trial testing the drug’s effectiveness. The 199 participants given Nuplazid tablets showed significant reduction of their hallucinations and delusions when compared to the placebo group.
However, Nuplazid is not without its risks. Like all other atypical antipsychotic drugs, it carries the FDA’s boxed warning regarding an increased risk of death among older people with dementia-related mental ailments. Other symptoms included swelling of the feet and ankles, nausea, and confusion.
More than one million Americans suffer from Parkinson’s disease, and doctors estimate they will diagnose another 50,000 cases every year.
If Parkinson’s Prevents You From Working, You May Qualify for Disability Benefits
As Parkinson’s disease may lead to slow movement, stiffness, loss of balance, speech problems, depression, and cognitive impairment, it can greatly impair a person’s ability to work both physically and mentally. If you or a loved one suffer from this condition and can no longer work and earn an income, the Disability Help Group can assist you with filing a disability benefits claim or appealing a denial.
You and your family do not need to suffer from the debilitating effects of Parkinson’s alone; let us help you get the benefits you need and deserve. Call us at 800-800-2009 or fill out our contact form to schedule a consultation with one of our Social Security disability advocates today.